DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma

The authors investigate the role of mitochondrial dynamics, specifically the fission protein DRP1, in multiple myeloma (MM) and its potential as a therapeutic target. They find that MM cells exhibit excessive mitochondrial fragmentation, which is linked to treatment resistance and poor patient outcomes. By inhibiting DRP1, either genetically or pharmacologically, they demonstrate significant anti-myeloma effects, suggesting that targeting mitochondrial fission could be a promising strategy for treating relapsed or refractory MM.